PMC

A. Week 12 serum OAS change from baseline plotted against absolute CD4⁺ T-cell count at baseline; estimated Spearman correlation r = 0.63 (90% CI, 0.15, 0.87).
B. Week 12 plasma HIV-1 RNA log₁₀ copies/mL changes from baseline plotted against absolute CD4⁺ T-cell count at baseline; r=-0.40 (90% CI, −0.76, 0.16)
C. IFIG levels at baseline, MFI, plotted against baseline CD4⁺ T-cell count; estimated Spearman correlation −0.81 (90% CI, −0.95, −0.38).
D. IFIG change from baseline at week 12, MFI, plotted against baseline CD4⁺ T-cell count; r = 0.76 (90% CI, 0.26, 0.94).

A. Week 12 plasma HIV-1 RNA changes from baseline (average of pre-entry and entry, log₁₀ copies/mL) plotted against week 12 plasma concentrations for pegylated interferon alpha-2a. Red triangles, 3 subjects with reduced dosing; black circles, remaining subjects; estimated Spearman correlation r = −0.11 (90% CI −0.60 to 0.44).
B. Week 12 plasma HIV-1 RNA changes from baseline (average of pre-entry and entry, log10 copies/mL) plotted against area under the concentration-time curve (weeks 0-12) for interferon. Red triangles, 3 subjects with reduced dosing; black circles, remaining subjects; r = 0.16 (90% CI, −0.39 to 0.63)

A. Plasma HIV-1 RNA, log₁₀ copies/mL, subject-specific trajectories shown in black, median values shown in blue. Vertical line shows study week at which last injection of pegylated-interferon occurred. The number of subjects with available data is shown at the top of the graph.
B. Plasma HIV-1 RNA changes from baseline, log₁₀ copies/mL, trajectories of subject-specific changes in red (three subjects with reduced dosing) and black (all other subjects). Horizontal line at zero (no change from baseline); vertical line at last weekly injection of study drug.
C. Median changes in CD4⁺ T-cell count (solid red lines) and percent (broken blue lines) by study week, intervals represent 90% CIs around the medians.

A. Median log₁₀ interferon (ng/mL; black squares, blacks solid line), median OAS change from baseline (fold-change; red diamonds, red broken line), median IFIG change from baseline (MFI; blue circles, blue dashed line) and median plasma HIV-1 RNA change from baseline (log10 copies/mL; green triangles, green broken line) plotted against study week. Intervals represent 90% CIs around medians. Y-axis truncated at 2.5. OAS fold-change CIs: week 1 (1.3 to 4.8), week 2 (1.7 to 8.0), week 3 (1.2 to 5.7), week 4 (1.2 to 5.0), week 6 (1.7 to 4.4), week 8 (1.2 to 7.7), week 10 (1.0 to 7.7), week 12 (1.2 to 4.5), week 13 (0.7 to 3.9) and week 18 (1.3 to 3.4).
B. Scatterplot of subject-specific changes in viral load against concurrent changes in OAS protein at week 0 (open black circle), week 1 (filled red circle; estimated Spearman correlation r = −0.75 [− 0.93, −0.28]), week 2 (blue square; r = −0.61 [− 0.87, −0.09]), and week 12 (green diamond; r = −0.51 [CI: −0.81, 0.02]).
C. Scatterplot of subject-specific changes in viral load against changes in IFIG at week 0 (open black circle), week 3 (filled red circle; r = -0.62 [90% CI -0.90, 0.02]), week 6 (blue square; r = -0.64 [-0.90, -0.02]), week 12 (green diamond; r = -0.74 [-0.93, -0.21]) and week 18 (open gray diamond; r = 0.07 [−0.64, 0.71]).